Search results
Results from the WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
rituximab: non-Hodgkin's lymphoma: Rituxan, MabThera 6750 7298 11 rivaroxaban: anticoagulant: Xarelto 6589 6234 12 aflibercept: Eylea 6551 5830 13 infliximab: Remicade 5908 7152 14 Pneumococcal conjugate vaccine: Prevnar 13 Prevenar 13 5802 5601 15 ustekinumab: Stelara 5156 4011 16 pregabalin: epilepsy: Lyrica 4970 5065
EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;
John faces ongoing chemotherapy estimated at $75,000 over two years. With a HELOC at a current variable rate of 9%, he can draw funds as needed and make interest-only payments of about $563 ...
(Reuters) -The U.S. Food and Drug Administration on Tuesday approved Johnson & Johnson's chemotherapy-free combination treatment for a type of non-small cell lung cancer, setting up a challenge ...
Ibritumomab tiuxetan is used to treat relapsed or refractory, low grade or transformed B cell non-Hodgkin's lymphoma (NHL), a lymphoproliferative disorder, and previously untreated follicular NHL in adults who achieve a partial or complete response to first-line chemotherapy. [5] The treatment starts with an infusion of rituximab.
The 15 drugs accounted for $41 billion, or 14%, of total Medicare Part D spending between Nov. 1, 2023, and Oct. 1, 2024.
Tositumomab is a murine monoclonal antibody which targets the CD20 antigen produced in mammalian cell. [1] It was combined with iodine-131 to produce a radiopharmaceutical for unsealed source radiotherapy, Iodine-131 Tositumomab (branded as Bexxar), for the treatment of non-Hodgkins lymphoma. [1]